From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Winning the War Against Human Parainfluenza Virus

by Global Biodefense Staff
October 24, 2014
Winning the War Against Human Parainfluenza Virus

Researchers at Griffith University’s Institute for Glycomics have moved a step closer to identifying a treatment for the Human parainfluenza virus (hPIV).

These highly-infectious viruses are the leading cause of upper and lower respiratory tract disease in young children, including Croup, responsible for thousands of hospitalizations in the developed world, and hundreds of thousands of deaths each year in developing countries.

To gain entry to human respiratory epithelial cells, hPIV attaches to carbohydrate receptors. They then enter cells and reproduce rapidly, causing illness.

The researchers used a multi-disciplinary approach to develop potent inhibitors that target a structural feature within the hPIV type 3 haemagglutinin-neuraminidase (hPIV-3 HN). The dual acting designer inhibitors efficiently block both hPIV cell entry and virion progeny release.

Institute Director Professor Mark von Itzstein said his Group’s research findings, published this week in Nature Communications, provided a new direction towards the discovery of anti-viral drugs against hPIV.

“To date, neither antiviral drugs nor vaccines are approved for clinical use against human parainfluenza virus, which reinforces the urgent need for new therapeutic discovery strategies,” said von Itzstein. “This discovery will advance research in the design and synthesis of new drugs that may stop infection by hPIV.”

Read the study at Nature Communications: Structure-guided discovery of potent and dual-acting human parainfluenza virus ​haemagglutinin–neuraminidase inhibitors.

Image: Transmission electron micrograph (TEM) of human parainfluenza virus Type-4a (HPIV-4). The incubation period for HPIVs is generally from 1 to 7 days. Credit: CDC

From Our Partners
Tags: Antivirals

Related Posts

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Pathogens

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Send in the Blow Flies: Using Insects to Sample Areas for Chemical Warfare Agents
CBRNE

Send in the Blow Flies: Using Insects to Sample Areas for Chemical Warfare Agents

April 11, 2022
Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses
Pathogens

Johns Hopkins: Chemical in Leafy Greens May Slow Growth of Coronaviruses

April 11, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC